Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

Market Cap	24.07B +4.6%
Revenue (ttm)	6.02B +8.9%
Net Income	1.23B +5.0%
EPS	1.21 +4.3%
Shares Out	1.02B
PE Ratio	19.58
Forward PE	19.11
Dividend	0.36 (1.52%)
Ex-Dividend Date	May 14, 2025

Volume	6,043,500
Average Volume	10,184,794
Open	23.75
Previous Close	23.75
Day's Range	23.70 - 24.04
52-Week Range	20.36 - 29.30
Beta	-0.28
RSI	47.24
Earnings Date	Apr 18, 2026

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine fumarate, injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, duloxetine hydrochloride enteric dissolving capsules, olan...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 5,923
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002262

Financial Performance

In 2024, SHE:002262's revenue was 5.70 billion, an increase of 13.01% compared to the previous year's 5.04 billion. Earnings were 1.14 billion, an increase of 10.28%.